Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

GWT-TUD GmbH

Home Clinical Trial Sponsors and OrganizationsGWT-TUD GmbH

GWT-TUD GmbH

Freiberger Str. 33, Dresden, Sachsen, Germany

Also known as:

tcc chemnitz

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

72

27 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

22

30.6%

Phase 3

12

16.7%

Phase 2

9

12.5%

Phase 4

5

6.9%

Not Applicable

1

1.4%

Trial Status Distribution

Active, not recruiting

26

36.1%

Completed

31

43.1%

Enrolling By Invitation

1

1.4%

Recruiting

5

6.9%

Terminated

8

11.1%

Unknown

1

1.4%

Clinical Trials

Trials sponsored by this organization (72)

Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining

Jul 202660 participants

VALIdation of a Treatment Decision Pathway for Andexanet Alfa

May 2024600 participants

Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffuse large B-cell lymphoma (DLBCL)

Active, not recruiting

Nov 2023334 participants

INvestigating SIGnificant Health TrendS in Growth Hormone Treatments Registry

Enrolling By Invitation

Jan 20221,500 participants

Study of the use of autologous platelet concentrate during pars-plana-vitrectomy for epiretinal gliosis and impending macular hole

Jan 202257 participants

Evaluation of risk factors for the development of diabetic retinopathy (DR) in patients with type 2 diabetes: comprehensive analysis with optical coherence tomography (OCT), VEGF and biomarkers of inflammatio

Jan 202232 participants

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Active, not recruiting

Oct 202170 participants

Determination of the effectiveness and safeness of the drug luspatercept in patients who suffering from a low risk type of cancer when blood-forming cells in the bone marrow become abnormal and having characterized by decreased red blood cells below normal.

Active, not recruiting

Aug 202170 participants

Page 1 of 9

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials72
Approvals
News

Back to Organizations